World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
100
Citations
68324
World Ranking
8107
National Ranking
267

Luca Gianni publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Luca Gianni sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 438 publications — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Luca Gianni D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Luca Gianni sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 100 D-Index — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Luca Gianni is affiliated with Vita-Salute San Raffaele University in Italy. Their research primarily focuses on medical and biomedical fields, with a strong emphasis on oncology and cancer-related studies.

The main fields of study covered by their work include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these areas, they have contributed especially to the subfields of:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Radiology, Nuclear Medicine and Imaging
  • Molecular Biology

Their research addresses various topics, notably in cancer biology and treatment, including:

  • HER2/EGFR in Cancer Research
  • Advanced Breast Cancer Therapies
  • Cancer Treatment and Pharmacology
  • Cancer Immunotherapy and Biomarkers
  • Breast Cancer Treatment Studies
  • Cancer Genomics and Diagnostics
  • Monoclonal and Polyclonal Antibodies Research

Their frequent co-authors include:

  • Giampaolo Bianchini
  • Pinuccia Valagussa
  • Claudio Zamagni
  • Giuseppe Viale
  • Matteo Dugo

Major venues where they have published multiple articles are:

  • Cancer Research
  • Journal of Clinical Oncology
  • Annals of Oncology
  • npj Breast Cancer
  • European Journal of Cancer

Some of their recent publications are:

  • "Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer", 2021, New England Journal of Medicine
  • "Treatment landscape of triple-negative breast cancer - expanded options, evolving needs", 2021, Nature Reviews Clinical Oncology
  • "Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial", 2020, The Lancet Oncology
  • "Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study", 2022, Annals of Oncology
  • "Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial", 2020, The Lancet Oncology

Best Publications

  • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

    Martine J. Piccart-Gebhart;Marion Procter;Brian Leyland-Jones;Aron Goldhirsch

  • Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity

    Giorgio Minotti;Pierantonio Menna;Emanuela Salvatorelli;Gaetano Cairo

  • Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    Patricia Cortazar;Lijun Zhang;Michael Untch;Keyur Mehta

  • Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

    Sunil Verma;David Miles;Luca Gianni;Ian E. Krop

  • Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

    Luca Gianni;Tadeusz Pienkowski;Young Hyuck Im;Laslo Roman

  • Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

    Giampaolo Bianchini;Justin M. Balko;Ingrid A. Mayer;Melinda E. Sanders

  • Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

    Luca Gianni;Wolfgang Eiermann;Vladimir Semiglazov;Alexey Manikhas

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    Aditya Bardia;Sara A Hurvitz;Sara M Tolaney;Delphine Loirat

  • Treatment of HER2-positive breast cancer: current status and future perspectives

    Carlos L. Arteaga;Mark X. Sliwkowski;C. Kent Osborne;Edith A. Perez

  • Triple-Negative Breast Cancer: An Unmet Medical Need

    Clifford A. Hudis;Luca Gianni

  • 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

    David Cameron;Martine J Piccart-Gebhart;Richard D Gelber;Richard D Gelber;Marion Procter

  • Triple-negative breast cancer: disease entity or title of convenience?

    Lisa Carey;Eric Winer;Giuseppe Viale;David Cameron

  • Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

    J Baselga;D Rischin;M Ranson;H Calvert

  • HER2-positive breast cancer

    Sibylle Loibl;Luca Gianni

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy

    José Baselga;Karen A. Gelmon;Shailendra Verma;Andrew Wardley

  • 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

    Luca Gianni;Tadeusz Pienkowski;Young Hyuck Im;Ling Ming Tseng

  • Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

    L Gianni;E Munzone;G Capri;F Fulfaro

  • European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

    E A Eisenhauer;W W ten Bokkel Huinink;K D Swenerton;L Gianni

  • Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.

    L Gianni;C M Kearns;A Giani;G Capri

Frequent Co-Authors

Pinuccia Valagussa
Pinuccia Valagussa University of Louisville
José Baselga
José Baselga Memorial Sloan Kettering Cancer Center
Michael Untch
Michael Untch Helios Klinikum Berlin-Buch
Michele Reni
Michele Reni Vita-Salute San Raffaele University
Javier Cortes
Javier Cortes Vall d'Hebron Hospital Universitari
Véronique Diéras
Véronique Diéras Institute Curie
Christian Jackisch
Christian Jackisch Breast Cancer Research Foundation
Massimo Falconi
Massimo Falconi Vita-Salute San Raffaele University
Claudio Doglioni
Claudio Doglioni Vita-Salute San Raffaele University
Giampaolo Merlini
Giampaolo Merlini University of Pavia

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

In addition to traditional medical programs, students interested in healthcare careers can explore a growing number of online degree options. For those seeking a fast entry into patient care, accelerated lpn programs online enable learners to become Licensed Practical Nurses in less time than traditional pathways.

For nurses aiming to specialize further, advancing from msn to pmhnp online programs can provide clinical expertise in psychiatric and mental health nursing, opening doors to in-demand roles. These pathways blend clinical experience with coursework and offer flexible schedules suited to working professionals.

If your passion leans towards healthcare leadership and management, consider an online master of health administration program. Many of these programs are both accessible and cost-effective. Prospective students should also explore the most affordable online mha programs to balance quality education with career goals and financial considerations.

Whether you are entering direct patient care or healthcare management, these online degree options offer flexibility and new pathways to rewarding careers in medicine.

Best Scientists Citing Luca Gianni

Trending Scientists

Recently Published Articles